Michael Cherny

For Corporates
Analyzing Healthcare M&A Trends: Q1 2024 Insights
Healthcare M&A activity remained robust in the first quarter of 2024, with 29 transactions vs. 28 in 2023. Biopharma was the most active healthcare subsector, representing 45% of deal volume, while Services activity remained dampened despite notable transactions such as Novo Holdings’ acquisition of Catalent. We expect Biopharma M&A activity to remain robust as large pharmaceutical companies attempt to fill revenue and pipeline gaps via acquisitions of late- or commercial-stage companies. We expect pre-commercial biopharma companies to continue pursue strategic alternatives, including mergers, private company mergers and cash-out transactions as a result of the dynamic capital markets environment.
LEARN MORE
For Investors
Sectors
Insights
About
- Firm
- Careers
- News
- Contact
- Transactions

Team
Research
Michael Cherny

Michael Cherny is a Senior Managing Director and Senior Research Analyst at Leerink Partners covering Healthcare Technology and Distribution.

Prior to joining the Firm in 2023, Michael’s most recent role was at Bank of America Merrill Lynch where he was Managing Director / Healthcare Technology & Distribution Analyst. Prior to Bank of America Merrill Lynch, Michael was the Healthcare Technology & Distribution Analyst at UBS Securities and held roles at Evercore ISI and Deutsche Bank within the healthcare and technology sector.

He earned his bachelor’s degree in business administration from Emory University.

Partner With Us

Contact Us